ATE315089T1 - Regulierung des menschlichen p2y1-ähnlichen g- protein gekoppelten rezeptors - Google Patents

Regulierung des menschlichen p2y1-ähnlichen g- protein gekoppelten rezeptors

Info

Publication number
ATE315089T1
ATE315089T1 AT01976066T AT01976066T ATE315089T1 AT E315089 T1 ATE315089 T1 AT E315089T1 AT 01976066 T AT01976066 T AT 01976066T AT 01976066 T AT01976066 T AT 01976066T AT E315089 T1 ATE315089 T1 AT E315089T1
Authority
AT
Austria
Prior art keywords
coupled receptor
asthma
disease
human
regulation
Prior art date
Application number
AT01976066T
Other languages
English (en)
Inventor
Shyam Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of ATE315089T1 publication Critical patent/ATE315089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
AT01976066T 2000-08-14 2001-08-10 Regulierung des menschlichen p2y1-ähnlichen g- protein gekoppelten rezeptors ATE315089T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22498900P 2000-08-14 2000-08-14

Publications (1)

Publication Number Publication Date
ATE315089T1 true ATE315089T1 (de) 2006-02-15

Family

ID=22843078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01976066T ATE315089T1 (de) 2000-08-14 2001-08-10 Regulierung des menschlichen p2y1-ähnlichen g- protein gekoppelten rezeptors

Country Status (9)

Country Link
US (3) US20040038879A1 (de)
EP (1) EP1311677B8 (de)
JP (1) JP2004506426A (de)
AT (1) ATE315089T1 (de)
AU (1) AU2001295454A1 (de)
DE (1) DE60116515T2 (de)
DK (1) DK1311677T3 (de)
ES (1) ES2258553T3 (de)
WO (1) WO2002014511A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2258553T3 (es) * 2000-08-14 2006-09-01 Actimis Pharmaceuticals, Inc. Regulacion del receptor acoplado a la proteina g humana del tipo p2y1.
US7312086B2 (en) 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
US20060240424A1 (en) * 2002-09-27 2006-10-26 Hisayo Inbe Regulation of human p2y15 g protein-coupled receptor
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
WO2005101004A2 (en) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1)
WO2006052007A1 (ja) * 2004-11-11 2006-05-18 Takeda Pharmaceutical Company Limited 血糖調節剤
CN107596371B (zh) * 2017-08-21 2021-01-26 南方医科大学 P2y1受体及其阻断剂在预防和治疗抗抑郁症和/或抗焦虑症中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981176A (en) * 1992-06-17 1999-11-09 City Of Hope Method of detecting and discriminating between nucleic acid sequences
FR2701955B1 (fr) * 1993-02-26 1995-05-24 Paris Val Marne Universite Facteur de croissance de la famille de l'HARP, procédé d'obtention et applications.
US5582988A (en) * 1994-09-15 1996-12-10 Johnson & Johnson Clinical Diagnostics, Inc. Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same
US5734040A (en) * 1996-03-21 1998-03-31 University Of Iowa Research Foundation Positively charged oligonucleotides as regulators of gene expression
US6924040B2 (en) * 1996-12-12 2005-08-02 United Technologies Corporation Thermal barrier coating systems and materials
CA2388865A1 (en) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Novel g protein-coupled receptors
IL149569A0 (en) * 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors
EP1246916A2 (de) * 1999-12-30 2002-10-09 Millennium Pharmaceuticals, Inc. 26904, 38911, and 39404, protein mit sieben-transmembran-domänen / an ein g-protein gekoppelte rezeptoren
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001243142A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1261710A2 (de) * 2000-03-08 2002-12-04 PHARMACIA & UPJOHN COMPANY G-protein gekoppelte rezeptoren
EP1297128A2 (de) * 2000-05-18 2003-04-02 Incyte Genomics, Inc. G-protein gekoppelte rezeptoren
WO2001087980A2 (en) * 2000-05-18 2001-11-22 Applera Corporation Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
ES2258553T3 (es) * 2000-08-14 2006-09-01 Actimis Pharmaceuticals, Inc. Regulacion del receptor acoplado a la proteina g humana del tipo p2y1.

Also Published As

Publication number Publication date
ES2258553T3 (es) 2006-09-01
EP1311677B8 (de) 2006-04-19
US20050148014A1 (en) 2005-07-07
WO2002014511A3 (en) 2002-07-11
US20040038879A1 (en) 2004-02-26
EP1311677A2 (de) 2003-05-21
US20060052329A1 (en) 2006-03-09
DK1311677T3 (da) 2006-05-22
DE60116515D1 (de) 2006-03-30
EP1311677B1 (de) 2006-01-04
DE60116515T2 (de) 2006-09-07
WO2002014511A2 (en) 2002-02-21
JP2004506426A (ja) 2004-03-04
AU2001295454A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
EP0867508A3 (de) Geruchs Rezeptor von dem 7-Transmembran-Rezeptor Familie - OLRCC15 Rezeptor
EP0875566A3 (de) Neuartiger G-Protein gekoppelter Rezeptor
EP0893498A3 (de) cDNS Klon die für einen humanen 7-Transmembranrezeptor kodiert
EP0875565A3 (de) Neuartiger G-Protein gekoppelter Rezeptor (HFGAN72Y)
EP0899332A3 (de) G-Protein gekoppelter Rezeptor HFIAO41
EP0892051A3 (de) CDNA Klon Heoad54 der für einen menschlichen 7-Transmembranrezeptur kodiert
EP0853126A3 (de) cDNA Klon HE8C341 der für einen menschlichen 7-transmembranrezeptor kodiert
WO2001094385A8 (en) Human hm74-like g protein coupled receptor
EP0885960A3 (de) Protein G-gekoppelter Rezeptor (H7TBA62)
DE60116515D1 (de) Regulierung des menschlichen p2y1-ähnlichen g-protein gekoppelten rezeptors
WO2001077320A3 (en) Regulation of human hm74-like g protein coupled receptor
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
EP0913471A3 (de) CDNA Klon HNEAA81 der für einen menschlichen 7-Transmembranrezeptur kodiert
WO2001070814A3 (en) Regulation of human rta-like g protein-coupled receptor
EP0881289A3 (de) 7TM Receptor (H2CAA71)
DK1287137T3 (da) Regulation af human alfa1A-adrenergreceptorlignende G-proteinkoblet receptor
WO2001070971A3 (en) Regulation of human mas oncogene-related g protein-coupled receptor
WO2001004139A3 (en) Human axor29 receptor
WO2001068702A3 (en) Regulation of human g protein-coupled receptor
EP0894854A3 (de) Neuen Splice-Varianten von dem Epstein-Barr Virus-induzierten G-Protein gekoppelter Rezeptor
WO2001068842A3 (en) Regulation of human p2y-like gpcr protein
WO2001068701A3 (en) Regulation of human seven transmembrane - like g protein - coupled receptor (7tm-gpcr)
WO2001085764A3 (en) Regulation of human p2y-like g protein-coupled receptor
EP0878542A3 (de) CDNS Klon HMTMF81 der für einen neuen menschlichen 7-Transmembranrezeptor kodiert
EP0853125A3 (de) cDNS Klon HNFJD15 der für einen menschlichen 7-Transmembranrezeptur kodiert

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1311677

Country of ref document: EP

REN Ceased due to non-payment of the annual fee